A Phase IIa, known-treatment without placebo, Multicenter Study of Single-Agent MOR00208, an Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma To assess the antitumor activity of single-agent MOR00208 in adult patients with relapsed or refractory NHL who have received at least one prior therapy containing rituximab as one of the treatments.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatment To determine the efficacy of a combination of MOR00208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in adult patients with R-R DLBCL.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to patients with active rheumatoid arthritis Safety and tolerability of multiple doses of MOR103 in patients with active rheumatoid arthritis.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Efficacy and Safety of MOR00208 used in combination with Idelalisib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma who have been previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor. Une étude pour évaluer l'efficacité et l'innocuité de MOR00208 utilisé en association avec l'idélalisib chez des patients atteints de Leucémie Lymphoïde Chronique ou du Petit Lymphome Lymphocytaire en rechute ou réfractaire prétraités avec un inhibiteur de la Tyrosine Kinase de Bruton (BTK) To determine the efficacy of the combination MOR00208 and idelalisib. Déterminer l’efficacité de l’association du MOR00208 et de l’idelalisib.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune